BCL2 and lymphoma: Consistent with the in vitro cell death assays using BH3 mimetic drugs targeting BCL-2 or MCL-1 in malignant Eμ-MYC lymphoma cells, we observed no differences in the expression of any of the BCL-2 family member genes (Fig. 5A).